“…The model rats were randomly assigned to 9 groups using the random number table method including sham group ( N = 12), CIBP group (TCI) ( N = 36), CIBP + PAR-2 inhibitor group (TCI + PI group) ( N = 6), CIBP + normal saline group (TCI + N group) ( N = 6), CIBP + PAR-2 control peptide group (TCI + PJ group) ( N = 6), CIBP + PAR-2 inhibitor + ERK activator group (TCI +PI + EA group) ( N = 6), CIBP + PAR-2 inhibitor + dimethyl sulfoxide (DMSO) group (TCI + PI + N) ( N = 6), CIBP + PAR-2 inhibitor + ERK activator + CREB inhibitor group (TCI + PI + EA + CI) ( N = 6), and CIBP + PAR-2 inhibitor + ERK activator + DMSO group (TCI + PI + EA + N) ( N = 6). The model rats were intrathecally injected with 10 µL PAR-2 inhibitor FSLLRY-NH2 (1 mmol/L, FSLLRY-NH2, CAS No.245329-02-6, MedChemExpress, Monmouth Junction, NJ, USA) [ 15 ], PAR-2 control peptide (LRGISL-NH2, Bachem Inc., Torrance, CA, USA), 10 µL ERK activator Dehydrocorydaline chloride (10 mg/kg, HY-N0674A, MedChemExpress) [ 16 ] and 10 µL CREB inhibitor KG-501 (70,485, Sigma-Aldrich, St. Louis, MO, USA) on the 13th d after the operation. The equivalent volume of normal saline (1 mmol/L) and DMSO were set as the corresponding controls.…”